Navigation Links
Drug-Eluting Stents Outperform Bare Stents in Heart Attack
Date:3/30/2008

ively, at 30 days and 12.3 percent vs. 9.9 percent, respectively, at eight months. The rates of minor and major bleeding did not differ in the two groups, but a marked drop in the blood platelet count -- a complication that could cause uncontrolled bleeding -- was more common among patients treated with abciximab (4.0 percent vs. 0.8 percent, p=0.004).

When comparing the two types of stents, investigators found an equivalent MACE rate at 30 days (3.9 percent vs. 5.9 percent, p=0.12) with sirolimus-eluting and bare-metal stents. However, at eight months, the MACE rate was significantly lower with drug-eluting stents (7.8 percent vs. 14.5 percent, p=0.0039). This difference was mainly driven by a 69 percent reduction in the need for a repeat procedure to reopen the treated coronary artery (3.2 percent with sirolimus-eluting stents vs. 10.2 percent with bare-metal stents, p=0.0004). The rates of death and repeat heart attack were similar, as was the incidence of stent thrombosis.

"Our study shows that tirofiban is 'noninferior' in its efficacy to abciximab in this high-risk patient population, and has a better safety profile," said Dr. Valgimigli. "We have also confirmed that, even in STEMI patients, drug-eluting stents are highly effective in reducing reintervention in the target vessel. More important, this came without an extra price to pay in terms of death, myocardial infarction or stent thrombosis."

Dr. Valgimigli will present the results of this study on Sunday, March 30 at 9:00 a.m. CDT in the Grand Ballroom, S100. This study will simultaneously publish in JAMA: Journal of the American Medical Association.

About SCAI

Headquartered in Washington, DC, the Society for Cardiovascular Angiography and Interventions is a 4,000-member professional organization representing invasive and interventional cardiologists in over 60 nations. SCAI's mission is to promote excellence in invasive and interventional cardiovascular medicine through
'/>"/>

SOURCE SCAI-ACCi2
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
2. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
3. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
4. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Medifast Outperforms American Diabetes Association Diet by Twice the Weight Loss According to Published Study
7. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
8. Stem Cell Research Provides Medical Breakthrough to Repair Heart Cell Damage Created by a Heart Attack
9. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
10. American Heart Association Journal Report: Reducing Kids Salt Intake May Lower Soft Drink Consumption, Reducing Obesity, High Blood Pressure and Later Health Risks
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... --  Heska Corporation (NASDAQ: HSKA ) - ... advanced veterinary diagnostic and other specialty veterinary products , ... attend The Benchmark Company, LLC,s Micro Cap Discovery Conference on ... at The Palmer House Hilton, 17 E. Monroe Street, ... p.m. Please email hska@haydenir.com or contact your Benchmark ...
(Date:11/26/2014)... 25, 2014  Array BioPharma Inc. (Nasdaq: ... its Chief Executive Officer, Ron Squarer ... conferences.  The public is welcome to participate ... Array BioPharma website:  www.arraybiopharma.com .Event: Piper Jaffray ...  Eastern Time Location: Palace Hotel, New York ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 ... (NYSE: AZN ) today announced that AMAGINE-2 TM ... of brodalumab in more than 1,800 patients with moderate-to-severe plaque ... ® (ustekinumab) and placebo at week 12. Brodalumab 210 ... group were each shown to be superior to Stelara on ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... As annual open enrollment season begins for ... are available to answer questions and provide guidance ... 15 to December 7, Medicare beneficiaries have the ... enroll in a new plan, if they so ...
... Inc. (OTCBB: ILNS), a biopharmaceutical company engaged in the ... treatment of Alzheimer,s and other neurological diseases today issued ... Chairman and CEO. Dear Shareholder, ... you about pertinent corporate and industry developments contemporaneous with ...
Cached Medicine Technology:CVS/pharmacy Ready to Provide Assistance During Medicare Part D Annual Enrollment Period 2Intellect Neurosciences Issues Letter to Shareholders 2Intellect Neurosciences Issues Letter to Shareholders 3Intellect Neurosciences Issues Letter to Shareholders 4Intellect Neurosciences Issues Letter to Shareholders 5Intellect Neurosciences Issues Letter to Shareholders 6Intellect Neurosciences Issues Letter to Shareholders 7Intellect Neurosciences Issues Letter to Shareholders 8Intellect Neurosciences Issues Letter to Shareholders 9
(Date:11/27/2014)... DressVe , the well-known trendy young women’s clothing retailer, ... during Nov. 29 – Dec. 3 2014. In the special ... to 90% off. In addition, free delivery is provided for ... http://www.dressve.com/ , Dresses that combine trendy styles and high ... personality and figure. The designers of DressVe.com know this point ...
(Date:11/27/2014)... November 28, 2014 Cyber Monday cannot ... Turks & Caicos. This boutique resort, ranked #1 ... announcing a few highly sought out openings before Christmas ... they are offering every seventh night complimentary if booked ... is having a January 2015 promotion where every fourth ...
(Date:11/27/2014)... Luciana Lagana and her husband Gregory ... feature film that received 9 awards at the 2014 Zed ... It is also an official selection of the 2014 PollyGrind ... cinematic career for James Noel, a young filmmaker who excels ... mystery, filmed in glorious black and white, watching Omadox will ...
(Date:11/27/2014)... "As a nurse I see patients ... urinary incontinence," said an inventor from Whiting, N.J. "I ... accessory to prevent leakage and keep them dry and ... leakage. This prevents stains on pants, skirts and bottoms, ... ensures that the individual has time to get to ...
(Date:11/27/2014)... News) -- Thanksgiving meals can pose a challenge for ... expert says. Many traditional Thanksgiving dishes -- such ... are gluten-free, but "when it comes to pies, stuffing, ... Dr. Anca Safta, director of the Gluten and Allergic ... in North Carolina, said in a center news release. ...
Breaking Medicine News(10 mins):Health News:DressVe.com Introduces Its 2014 Special Monday Sales To The Global Customers 2Health News:The Tuscany on Grace Bay, Top-Rated TripAdvisor Resort in the Turks & Caicos Islands, Offers Special Pre-Christmas & January 2015 Promotions! 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 3Health News:Expert Shares Gluten-Free Thanksgiving Tips 2
... amphetamine abuse in the Asia-Pacific region has hit high levels ... problem threatening Asia that is this big is a problem ... Australia as is the security of Australia in terms of ... the United Nations Office of Drugs and Crime told AFP. ...
... in building an extensive catalog of information about how ... ,This so-called "Connectivity Map" will be able to ... wrote in the latest issue of Science. ... published in the journal Cancer Cell, may accelerate the ...
... the count of consultants employed in Scotland's hospitals went ... British Medical Association has indicated that the replenishment hardly ... Service. From the recent figures published, it is evident ... NHS is inadequate to meet the growing demands. ...
... Scientists at the University of California, San Diego and ... by Bacillus thuringiensis, a bacterium sprayed// on crops by ... at treating hookworm infections in laboratory animals. ,Their ... the Proceedings of the National Academy of Sciences, could ...
... develop breast cancer in her life. But how much do ... cancer specialists from the University of Michigan Comprehensive Cancer Center ... And in some cases the fear paralyzes women and prevents ... treatment. ,Here, experts debunk some of the most ...
... common allergies like asthma, pollen and hayfever that afflict millions ... may occur indirectly due to too much cleanliness as it ... that have lived with humans for millions of years. As ... substances like grass pollen. ,This theory was exploited ...
Cached Medicine News:Health News:Genetic Map Reveals How Drugs Fight Diseases: Study 2Health News:Bacterial Protein Shows Promise in Treating Intestinal Parasites 2Health News:Bacterial Protein Shows Promise in Treating Intestinal Parasites 3Health News:16 Common Myths About Breast Cancer 2Health News:16 Common Myths About Breast Cancer 3Health News:16 Common Myths About Breast Cancer 4Health News:16 Common Myths About Breast Cancer 5
... automated, easy to operate and maintain. The ... by flexible snap-seal pockets which minimize the ... of the water. Offered in two-, four-, ... accommodate bags of various sizes. ThermoLine Thawing ...
Inquire...
... The Dengue virus belongs to the Flavavirus ... commonly throughout the tropics.,Symptoms of Dengue fever ... pain in the back and limbs, lymphadenopathy,maculopapular ... for professional use as an aid in ...
... This test device is intended ... of IgG and IgM antibodies ... serum. The test is used ... diagnosis of Dengue viral infection ...
Medicine Products: